G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD

References

• Smith TJ, Bohlke K, Lyman GH, American Society of Clinical Oncology, et al. Recommendations for the Use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199–3212.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Myeloid Growth Factors (Version 2.2020). 2020 [cited 2020 Jul 4]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf
   Google Scholar
• Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22:416–423.
   PubMed Web of Science ®Google Scholar
• Ringden O, Hassan Z, Karlsson H, et al. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation. 2010;90:1022–1029.
   PubMed Web of Science ®Google Scholar
• Remberger M, Naseh N, Aschan J, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant. 2003;32:217–223.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Lee S, Zhu X, et al. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23:1417–1421.
   PubMed Web of Science ®Google Scholar
• CIBMTR. Instructions for Post-Transplant Essential Data (Post-TED) Form (Version 2). 2012 Aug 1. Available from: https://www.cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/Documents/post-ted-instruction.pdf
   Google Scholar
• Ozcan M, Ustün C, Akçağlayan E, et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;27:499–505.
   PubMedGoogle Scholar
• Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000;96:80–85.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Loberiza FR, Jr., Ringden O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006;107:1712–1716.
   PubMed Web of Science ®Google Scholar
• Ho VT, Mirza NQ, Junco Dd D, et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant. 2003;32:771–775.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood. 2001;97:3405–3410.
   PubMed Web of Science ®Google Scholar
• Stinson TJ, Adams JR, Bishop MR, et al. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2000;26:663–666.
   PubMedGoogle Scholar
• Dekker A, Bulley S, Beyene J, et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006;24:5207–5215.
   PubMed Web of Science ®Google Scholar
• Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685–3691.
   PubMed Web of Science ®Google Scholar
• Savani BN, Labopin M, Blaise D, et al. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica. 2016;101:256–262.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Kim S, Maciejewski JP, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95:2269–2274.
   PubMed Web of Science ®Google Scholar
• Pan L, Delmonte J, Jr., Jalonen CK, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422–4429.
   PubMed Web of Science ®Google Scholar
• Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol. 2004;79:209–215.
   PubMed Web of Science ®Google Scholar
• Initiative GO-GaB. FDA approves filgrastim biosimilar Nivestym. 2018.
   Google Scholar
• Staff TCfB. FDA Approves Coherus' Pegfilgrastim Biosimilar, Udenyca. The Center for Biosimilars; 2018.
   Google Scholar
• Staff TCfB. Mylan Confirms That It Has Launched Fulphila in the United States. The Center for Biosimilars; 2018.
   Google Scholar
• Torres Gomez A, Jimenez MA, Alvarez MA, et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol. 1995;71:65–70.
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Choi SJ, et al. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:591–599.
   PubMed Web of Science ®Google Scholar
• Ciernik IF, Schanz U, Gmur J. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant. 1999;24:147–151.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–2239.
   PubMed Web of Science ®Google Scholar
• Bhatia S. Cause-specific late mortality after allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2019;2019:626–629.
   PubMedGoogle Scholar
• Jonesn’ CA, Fernandez L, Mesa OA, et al. Burden of cost in chronic graft versus host disease following hematopoietic stem cell transplantation: predictions for the next decade. Value in Health. 2015;18:A842.
   Web of Science ®Google Scholar